The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside

A substantial reduction in the amount and quality of collagen leads to age-related deterioration of the elasticity and firmness of the skin. In recent years, multiple compounds have been developed aimed at reversing the molecular features of dermal aging. One such target for aging reversal is collag...

Descripción completa

Detalles Bibliográficos
Autores principales: Rovero, Paolo, Malgapo, Dennis Malvin Hernandez, Sparavigna, Adele, Beilin, Ghislaine, Wong, Vincent, Lao, Ma Purita
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760069/
https://www.ncbi.nlm.nih.gov/pubmed/36540724
http://dx.doi.org/10.2147/CCID.S374295
_version_ 1784852377092751360
author Rovero, Paolo
Malgapo, Dennis Malvin Hernandez
Sparavigna, Adele
Beilin, Ghislaine
Wong, Vincent
Lao, Ma Purita
author_facet Rovero, Paolo
Malgapo, Dennis Malvin Hernandez
Sparavigna, Adele
Beilin, Ghislaine
Wong, Vincent
Lao, Ma Purita
author_sort Rovero, Paolo
collection PubMed
description A substantial reduction in the amount and quality of collagen leads to age-related deterioration of the elasticity and firmness of the skin. In recent years, multiple compounds have been developed aimed at reversing the molecular features of dermal aging. One such target for aging reversal is collagen degradation or turnover. SA1-III is a decapeptide (Ac-Met-Gly-Lys-Val-Val-Asn-Pro-Thr-Gln-Lys-NH(2)), also known as KP1, formally derived from the C-terminal portion of serpin A1, an agent known as a physiological inhibitor of neutrophil elastase, and has been the subject of laboratory and clinical studies determining its effects on modulation of collagen turnover as well as the treatment of age-associated changes of the face. This review aims to provide a bio-inspired approach focusing on the latest scientific studies that describe the compound, as well as a comprehensive appraisal of laboratory and clinical tests on skincare formulations enriched with sA1-III.
format Online
Article
Text
id pubmed-9760069
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-97600692022-12-19 The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside Rovero, Paolo Malgapo, Dennis Malvin Hernandez Sparavigna, Adele Beilin, Ghislaine Wong, Vincent Lao, Ma Purita Clin Cosmet Investig Dermatol Review A substantial reduction in the amount and quality of collagen leads to age-related deterioration of the elasticity and firmness of the skin. In recent years, multiple compounds have been developed aimed at reversing the molecular features of dermal aging. One such target for aging reversal is collagen degradation or turnover. SA1-III is a decapeptide (Ac-Met-Gly-Lys-Val-Val-Asn-Pro-Thr-Gln-Lys-NH(2)), also known as KP1, formally derived from the C-terminal portion of serpin A1, an agent known as a physiological inhibitor of neutrophil elastase, and has been the subject of laboratory and clinical studies determining its effects on modulation of collagen turnover as well as the treatment of age-associated changes of the face. This review aims to provide a bio-inspired approach focusing on the latest scientific studies that describe the compound, as well as a comprehensive appraisal of laboratory and clinical tests on skincare formulations enriched with sA1-III. Dove 2022-12-14 /pmc/articles/PMC9760069/ /pubmed/36540724 http://dx.doi.org/10.2147/CCID.S374295 Text en © 2022 Rovero et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Rovero, Paolo
Malgapo, Dennis Malvin Hernandez
Sparavigna, Adele
Beilin, Ghislaine
Wong, Vincent
Lao, Ma Purita
The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside
title The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside
title_full The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside
title_fullStr The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside
title_full_unstemmed The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside
title_short The Clinical Evidence-Based Paradigm of Topical Anti-Aging Skincare Formulations Enriched with Bio-Active Peptide SA1-III (KP1) as Collagen Modulator: From Bench to Bedside
title_sort clinical evidence-based paradigm of topical anti-aging skincare formulations enriched with bio-active peptide sa1-iii (kp1) as collagen modulator: from bench to bedside
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760069/
https://www.ncbi.nlm.nih.gov/pubmed/36540724
http://dx.doi.org/10.2147/CCID.S374295
work_keys_str_mv AT roveropaolo theclinicalevidencebasedparadigmoftopicalantiagingskincareformulationsenrichedwithbioactivepeptidesa1iiikp1ascollagenmodulatorfrombenchtobedside
AT malgapodennismalvinhernandez theclinicalevidencebasedparadigmoftopicalantiagingskincareformulationsenrichedwithbioactivepeptidesa1iiikp1ascollagenmodulatorfrombenchtobedside
AT sparavignaadele theclinicalevidencebasedparadigmoftopicalantiagingskincareformulationsenrichedwithbioactivepeptidesa1iiikp1ascollagenmodulatorfrombenchtobedside
AT beilinghislaine theclinicalevidencebasedparadigmoftopicalantiagingskincareformulationsenrichedwithbioactivepeptidesa1iiikp1ascollagenmodulatorfrombenchtobedside
AT wongvincent theclinicalevidencebasedparadigmoftopicalantiagingskincareformulationsenrichedwithbioactivepeptidesa1iiikp1ascollagenmodulatorfrombenchtobedside
AT laomapurita theclinicalevidencebasedparadigmoftopicalantiagingskincareformulationsenrichedwithbioactivepeptidesa1iiikp1ascollagenmodulatorfrombenchtobedside
AT roveropaolo clinicalevidencebasedparadigmoftopicalantiagingskincareformulationsenrichedwithbioactivepeptidesa1iiikp1ascollagenmodulatorfrombenchtobedside
AT malgapodennismalvinhernandez clinicalevidencebasedparadigmoftopicalantiagingskincareformulationsenrichedwithbioactivepeptidesa1iiikp1ascollagenmodulatorfrombenchtobedside
AT sparavignaadele clinicalevidencebasedparadigmoftopicalantiagingskincareformulationsenrichedwithbioactivepeptidesa1iiikp1ascollagenmodulatorfrombenchtobedside
AT beilinghislaine clinicalevidencebasedparadigmoftopicalantiagingskincareformulationsenrichedwithbioactivepeptidesa1iiikp1ascollagenmodulatorfrombenchtobedside
AT wongvincent clinicalevidencebasedparadigmoftopicalantiagingskincareformulationsenrichedwithbioactivepeptidesa1iiikp1ascollagenmodulatorfrombenchtobedside
AT laomapurita clinicalevidencebasedparadigmoftopicalantiagingskincareformulationsenrichedwithbioactivepeptidesa1iiikp1ascollagenmodulatorfrombenchtobedside

Ejemplares similares